Literature DB >> 10470182

Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.

T Heinze1, S Jonas, A Kärsten, P Neuhaus.   

Abstract

UNLABELLED: Mutations in the p53 gene are the most frequently reported somatic gene alteration in human cancer. Overexpression of the oncogene c-erb B2 takes place also in many human carcinomas, esp. in cancers of the breast, colon and ovary. High values of both oncogenes correlate with poor prognosis. We analysed the concentration of p53 in tumor cytosols of 34 primary advanced HCC and with the clinical outcome and survival time. p53 was analysed in the tumor cytosol by luminometric immunoassay (LIA) using monoclonal antibodies detecting wild type and mutant p53 protein. C-erb B2 protein is analysed by a monoclonal ELISA. p53 values vary from 0 to 8.1 ng/mg protein (p) with a median = 0.1 ng/mg p. C-erb B2 values range from 0.02 to 4.53 U/microgram p with a median = 0.43 U/microgram p. Patients with p53 values > 0.1 ng/mg p. had shorter 1 year (20%) and 2 year (13%)--survival times compared to 60% and 20% in patients with p53 values < 0.1 ng/mgp. Patients with cerbB2 > 0.43 U/microgram p. had significantly shorter 1 year (20%) and 2 year survival times (10%) than patients with values < 0.43 U/microgram p (1 year survival = 56% and 2 year survival = 22%; p < 0.05).
CONCLUSION: p53 and c-erb B2 seem to be valuable prognostic factors in HCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470182

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.

Authors:  Dénes Görög; János Regöly-Mérei; Sándor Paku; László Kopper; Péter Nagy
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

Review 2.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

3.  Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.

Authors:  Z-H Xian; S-H Zhang; W-M Cong; W-Q Wu; M-C Wu
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

4.  Network-Pharmacology-Based Study on Active Phytochemicals and Molecular Mechanism of Cnidium monnieri in Treating Hepatocellular Carcinoma.

Authors:  Shakeel Ahmad Khan; Terence Kin Wah Lee
Journal:  Int J Mol Sci       Date:  2022-05-12       Impact factor: 6.208

Review 5.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

6.  Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.

Authors:  George G Chen; Juanita L Merchant; Paul B S Lai; Rocky L K Ho; Xu Hu; Morihiro Okada; Sheng F Huang; Albert K K Chui; David J Law; Yong G Li; Wan Y Lau; Arthur K C Li
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

7.  A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

Authors:  Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O'Neil; Ruey-Min Lee; Mark Zalupski; Janet Dancey; Helen Chen; Michael Grever; Charis Eng; Miguel Villalona-Calero
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

8.  TOP2A amplification and overexpression in hepatocellular carcinoma tissues.

Authors:  Ravat Panvichian; Anchalee Tantiwetrueangdet; Napat Angkathunyakul; Surasak Leelaudomlipi
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

9.  Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.

Authors:  Juliana F Ortega; Aline de Conti; Volodymyr Tryndyak; Kelly S Furtado; Renato Heidor; Maria Aderuza Horst; Laura Helena Gasparini Fernandes; Paulo Eduardo Latorre Martins Tavares; Marta Pogribna; Svitlana Shpyleva; Frederick A Beland; Igor P Pogribny; Fernando Salvador Moreno
Journal:  Oncotarget       Date:  2016-04-26

Review 10.  HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.

Authors:  Nicola Fusco; Silvano Bosari
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.